A local biotech company has secured a six-figure grant.
TriAltus Bioscience has been awarded a $256,576 Phase I Small Business Technology Transfer (STTR) grant from the National Institutes of Health for its project called “Universal affinity membrane chromatography for rapid, one-step purification of proteins" that aims to make use of TriAltus’ patented protein purification technology.
The highly competitive STTR program funds joint research proposals from small businesses that partner with universities and nonprofits. TriAltus will work in tandem with Dr. Scott M. Husson of Clemson University, who will serve as principal investigator on the project, as well as Dr. Dmitry Vassylyev, TriAltus’ co-founder and professor of biochemistry and molecular biology at UAB.
“We are grateful for this crucial NIH funding, which will support advances in our state-of-the-art protein purification technology,” said TriAltus CEO Bob Shufflebarger. “This funding further validates our platform’s potential to become the first near-universal affinity membrane for the purification of proteins.”
The successful completion of these Phase I studies will facilitate follow-on funding for TriAltus’ investigations via the Phase II STTR/SBIR program.
TriAltus develops innovative tools for the production and purification of genetically engineered proteins.
